Malmö, Sweden

Kristian Riesbeck

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Protein Interaction Research. Top assignees: Arne Forsgren Ab, Arne Forsgren Et Al., Imperial College Innovations Limited. Active years: 2002-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kristian Riesbeck. Retrieved from https://idiyas.com/inventor/kristian-riesbeck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 46.7

 

 

Average Co-Inventor Count = 2.3

ph-index = 5

Forward Citations = 62(Granted Patents)


Location History:

  • Malmö, CH (2013)
  • Malmo, SE (2016 - 2019)
  • Malmö, SE (2002 - 2022)

Company Filing History:


Years Active: 2002-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Protein E
Moraxella Catarrhalis
Epithelial Cells
Extracellular Matrix
Complement System
Anticoagulant Fusion Protein
Immunoglobulin D
Cell Membrane
15 patents (USPTO):Explore Patents

Title: Kristian Riesbeck: Innovator in Protein Research

Introduction

Kristian Riesbeck is a prominent inventor based in Malmö, Sweden. He has made significant contributions to the field of protein research, holding a total of 15 patents. His work focuses on surface exposed proteins and their applications in immunology and vaccine development.

Latest Patents

One of his latest patents involves a surface exposed protein known as protein E (pE). This invention relates to a virulence factor that can be detected and has an amino acid sequence as described in SEQ ID NO 1. The patent also covers an immunogenic fragment of this protein, as well as a recombinant immunogenic protein (pE(A)) and its truncated variants. Additionally, it describes nucleic acid sequences, vaccines, plasmids, phages, non-human hosts, recombinant nucleic acid sequences, fusion proteins, and fusion products. Another significant patent discusses the interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins, and the complement system. This disclosure highlights the ability of surface proteins to interact with epithelial cells via cell-associated fibronectin and laminin, and their role in inhibiting the complement system, making them useful in vaccine preparation.

Career Highlights

Throughout his career, Kristian has worked with notable companies, including Arne Forsgren AB and Arne Forsgren et al. His innovative research has positioned him as a key figure in the field of protein science.

Collaborations

Kristian has collaborated with esteemed colleagues such as Arne Forsgren and Anthony Dorling, further enhancing the impact of his research.

Conclusion

Kristian Riesbeck's contributions to protein research and vaccine development are noteworthy. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge in this critical area.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…